Theracryf PLC Share Chat (TCF)

CJ have you recently been attending Amdram ?

As you stated yourself DSFlat: These forthcoming findings are crucial for deeper investigations of SFX-01 molecular mechanisms.

Never ending deeper investigation and clinical trials, how long will this take and who will pay for it? You could scroll back five years on these messageboards and it was the same discussions. Promising data requiring further analysis. TCF needs money, lots of it and quickly and it’s not going to happen.

No red dot,

It could be that TCF are looking to save money on the type and the cost of RNS's, which could make some sense...

Maybe waiting to get some additional SFX-01 info Ducks lined up ?

As you point out it should spark medical interest

Https://bmccancer.biomedcentral.com/counter/pdf/10.1186/s12885-024-12536-8.pdf

Can't believe I missed this was there a red dot ? The PDF is 24 pages long appears to be excellent research and peer reviewed by BMC ( Bio Med Central )in their Cancer Journal in the US .I cannot understand why the company did not issue a proper RNS Is it because it was peer reviewed by BMC which is an open access journal and is free to anyone and there may be a lack of quality in the peer review ?Nevertheless I am sure it will spark a lot of medical interest and give hope to families with children this devastating disease

Https://bmccancer.biomedcentral.com/counter/pdf/10.1186/s12885-024-12536-8.pdf

Can't believe I missed this was there a red dot ? The PDF is 24 pages long appears to be excellent research and peer reviewed byB

I have to say I'm surprised the BOD haven't given more weight to this news, a 'reach' RNS and as yet none of the old media coverage.

Given the new format in the recent investor R&D presentation my feeling is that TCF know they have something good enough to entice big players and have given up with the retail promotions to some degree.

Conclusions

In summary, our results provide evidence for the antitumour properties of SFX-01 in preclinical models of RMS tumours, both as a standalone treatment and in combination with irradiation. These forthcoming findings are crucial for deeper investigations of SFX-01 molecular mechanisms against RMS and for setting up clinical trials in RMS patients in order to use the SFX-01/IR co-treatment as a promising therapeutic approach, particularly in the clinical management of aggressive RMS disease.

379 accesses to the DATA on BMC, Pubmed circulating the DATA.

https://pubmed.ncbi.nlm.nih.gov/38977944/

Anyone have any thoughts on this...

I make my living from buying unloved bombed out stocks. My ISA is at a all time high and I'm confident of turning the initial starting pot of £300 all those years ago into £1 million. It's already in 6 figures.

I see value here newuncle, you have only posted that because of my views on CPX and GPL which are both overvalued fluff being pumped by the masses.

I'm guessing you only go for the showers ;-)

His dad is massive too......and he knows all the bouncers.

Watch yourself.

DS, I am going to let that one pass this time as you don’t know who I am or what I’m capable of. But I do hold black belts in jujutsu and karate so I’m not someone you want to trifle with.

We don't all agree Marv

Three likes for the dumbest post I've seen on here for some time...

Probably one of those multiple ID and low IQ posters

I did wonder what made you buy shares in this on Wednesday Davey? We all agree that Stalicla aren’t paying us any money now this year. Chances of any new deals signed for SFX-01 is nil. So what’s the thinking?

Davey,

Why are you still in this bow wow stock? I honestly thought you had a brain in that thick skull of yours

Chasers yesterday getting mugged for having no patience. None of the sales today are mine. I would buy more but I bought 1.5 million in total yesterday which is enough for now

'Thank you for your email. We'll get in contact with the supplier to chase this up. We do get RNS Reach articles but recently there's been a few issues with the supplier sending them over.'

Blimey this is how the mm's make a killing, sell millions do not move, wait patiently then people sell it back to them for 10-20% lower easy money

Spread is awful 0.81-0.923p, considering somebody bought 550k at 0.925p yesterday the mm's are being very tight as normal

Marvin. That might be right for you but for others that buy in at lows there is a chance to make money, look at some stocks that have dropped 90%+ then go and do 5-50 bag returns. For you if you are not averaging down there is little chance of your money back but for others in sub 1p there is a chance to make money

Antitumour effects of SFX-01 molecule in combination with ionizing radiation in preclinical and in vivo models of rhabdomyosarcoma

Methods

RH30, RH4 (alveolar RMS), RD and JR1 (embryonal RMS) cell lines as well as mouse xenograft models of RMS were used to evaluate the biological and molecular effects induced by SFX-01 treatment. Flow cytometry and the modulation of key markers analysed by q-PCR and Western blot were used to assess cell proliferation, apoptosis, autophagy and production of intracellular reactive oxygen species (ROS) in RMS cells exposed to SFX-01. The ability to migrate and invade was also investigated with specific assays. The possible synergistic effects between SFX-01 and ionising radiation (IR) was studied in both the in vitro and in vivo studies. Student’s t-test or two-way ANOVA were used to test the statistical significance of two or more comparisons, respectively.

Results

SFX-01 treatment exhibited cytostatic and cytotoxic effects, mediated by G2 cell cycle arrest, apoptosis induction and suppression of autophagy. Moreover, SFX-01 was able to inhibit the formation and the proliferation of 3D tumorspheres as monotherapy and in combination with IR. Finally, SFX-01, when orally administered as single agent, displayed a pattern of efficacy at reducing the growth of tumour masses in RMS xenograft mouse models; when combined with a radiotherapy regime, it was observed to act synergistically, resulting in a more positive outcome than would be expected by adding each exposure alone.

Conclusions

In summary, our results provide evidence for the antitumour properties of SFX-01 in preclinical models of RMS tumours, both as a standalone treatment and in combination with irradiation. These forthcoming findings are crucial for deeper investigations of SFX-01 molecular mechanisms against RMS and for setting up clinical trials in RMS patients in order to use the SFX-01/IR co-treatment as a promising therapeutic approach, particularly in the clinical management of aggressive RMS disease.

https://bmccancer.biomedcentral.com/articles/10.1186/s12885-024-12536-8

THERACRYF PLC - Research and Development Update

https://youtu.be/a3bYtaY2URw?si=5gggxeyxG1hYkQWJ

The presentation from 3 weeks ago (not many views)

SFX-01 could be heading towards treatments for Glioblastoma, Rhabdomyosarcoma and Autism.

This is one of the worst shares I’ve ever invested in, currently sitting on a loss of £16k. I’ve been checking for a RNS each morning for about a year hoping to see news of Stalicla paying up but it never arrives.

I think the chance of this succeeding is around 5%, but no way will the share price increase 20 times to account for that risk. Therefore there is no value here, we all must face it that we got it wrong and will take a big loss.

Well, you might get a little spike from this update, and I am waiting to see if this chat board gets a bunch of rampy posts in the days ahead, but IMO it is not transformational material.

The company has issued loads of these types of scientific updates over the years. Unless it is quickly followed up by a JV of some sort with a quality pharma name, or a new funding partner to cover all the costs of progressing this, then so what?

I appreciate that this post probably comes across as quite terse, but I genuinely think we have seen this story before and for me, it simply does not change a thing.

If it was Stal resolution news for example, and agreement of payment on the terms as initially outlined, then my post would be different.

Anyway, good luck to those of you who feel differently. And this is AIM, so you might get a nice spin on the fruit machine of SP movement here for a bit, regardless of this. Which is what I think some of you are plumping for and know this to be and nothing more, in all probability.

And that is fine too. You either make money in the market or lose it. Everything else is simply noise.

Blue dave.

The beauty of a overhang is people can buy into great news without having to pay 50% higher like most do in this market.

Still stock available at 0.885p I just took another 250k

RNS Number : 9045V

Theracryf PLC

10 July 2024

https://www.londonstockexchange.com/news-article/TCF/publication-of-peer-reviewed-data-on-sfx-01/16562071